

6 PROGRAMS IN LATE-STAGE DEVELOPMENT, PHASE 3 TRIAL RESULTS IMMINENT

10 November 2021



FORWARD LOOKING STATEMENTS

This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Neuren can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors.


TREATING NEURODEVELOPMENTAL DISORDERS

Rett	Fragile X	Phelan-McDermid	Angelman	Pitt Hopkins	Prader-Willi
<i>MECP2</i>	<i>FMR1</i>	<i>SHANK3</i>	<i>UBE3A</i>	<i>TCF4</i>	<i>15q11-q13</i>











Impaired communication between neurons, abnormal formation/pruning of dendrites & chronic inflammation

Neuren's drugs target the critical role of IGF-1 in this upstream process, using analogs of peptides that can be taken orally as liquids



Severe impact on nearly every aspect of life		
walking and balance issues	anxiety and hyperactivity	seizures
speech impairment	intellectual disability	breathing irregularities
impaired hand use	sleep disturbance	gastrointestinal problems

LEADING PIPELINE IN NEURODEVELOPMENTAL DISORDERS

Compound	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Commercial Partner	
Trofinetide	Rett syndrome ¹					<i>Results expected Q4 2021</i>	 (North America)
	Fragile X syndrome ¹						 (North America)
NNZ-2591	Phelan-McDermid syndrome ²			<i>Results expected H2 2022</i>			
	Angelman syndrome ²			<i>Results expected H2 2022</i>			
	Pitt Hopkins syndrome ²			<i>Results expected H2 2022</i>			
	Prader-Willi syndrome ³			<i>Commence expected mid-2022</i>			

¹ Orphan Drug designation in US and EU, Fast Track designation in US

² Orphan Drug designation in US and EU ³ Orphan Drug designation in US

TRANSFORMING MILESTONES IMMINENT

- **Results before the end of 2021 for trofinetide Phase 3 trial in Rett syndrome**
 - Partnered with Acadia (NASDAQ:ACAD) for North America, Neuren has access to all US data for ex-North America registration
 - ACADIA funds development and commercialisation for North America
 - Neuren receives up to US\$455m milestone payments, plus double digit % royalties, plus one third of RPD Priority Review Voucher value
 - Positive Phase 3 results also expected to enable Neuren to partner in Europe and Asia

- **Phase 2 trials for NNZ-2591 in 4 disorders**
 - **Large potential upside** - multiple indications and global rights retained
 - Potential markets for NNZ-2591 more than 5 times Rett syndrome

TROFINETIDE FOR RETT SYNDROME

RETT SYNDROME OPPORTUNITY

Estimates	US	Europe	Japan	China urban	Other Asia
Potential patients ¹	10,000	13,000	3,000	28,000	6,000
Patients currently identified	5,000	4,000	1,000	2,000	'00s


¹ Potential patient estimates derived by applying the mid-point of the published prevalence estimate range to the populations under 60 years

- ▣ Peak annual sales potential in US at least US\$500m²
- ▣ Neuren potential revenue over 2022 and 2023 for Rett syndrome in the US alone of A\$111 million³ plus double-digit percentage royalties on net sales
- ▣ Diagnosis rates expected to increase with awareness and accelerate with availability of a treatment

² Acadia 2Q18 Earnings Call presentation and Jefferies Healthcare Conference 2 June 2021

³ Assuming a New Drug Application (NDA) is approved by the FDA, the product is launched in the US, US\$33m is received as one third share of the value of a Rare Pediatric Disease Priority Review Voucher if awarded upon approval of a NDA, and a USD/AUD exchange rate of 0.75


RETT SYNDROME PHASE 3 PROGRAM




- LAVENDER™ top-line results are imminent
 - ~180 females aged 5 to 20 years
 - RSBQ (caregiver) and CGI-I (physician) at 12 weeks are co-primary efficacy endpoints - both were positive in the Phase 2 trial
- Program includes DAFFODIL™ safety/PK trial in females aged 2 to 5 years
- Potential marketing approval in 2022 with Priority Review

RETT SYNDROME PHASE 2 - RSBQ AND CGI-I

Clinical improvement measured by RSBQ



Clinical improvement measured by CGI-I



RSBQ is a caregiver rating, reflecting the severity of the syndrome. Mean improvements for trofinetide and placebo were, respectively, 16% and 6%

CGI-I is a clinician rating of how much the subject's overall illness has improved or worsened. 22% of subjects on trofinetide received a score of 2 ("much improved") compared with 4% of subjects on placebo

RSBQ and CGI-I measure overall syndrome rather than a particular symptom, reflecting heterogeneity of symptoms and disease-modifying action of trofinetide

Publication: <https://n.neurology.org/content/early/2019/03/27/WNL.0000000000007316>

MAXIMISING PROBABILITY OF SUCCESS

- The Phase 3 co-primary endpoints were both positive in the Phase 2 trial
- In the Phase 2 trial clinical improvement continued increasing through to end of treatment - the Phase 3 trial at 12 weeks is twice the duration of the Phase 2 trial
- The Phase 3 sample size at approx. 90 per group is more than 3 times the Phase 2 sample size – much greater statistical power to detect a difference between active and placebo
- The dosing regimen in the active group for the Phase 3 trial is optimised, informed by the PK-PD analyses of the Phase 2 subjects
- The age range for the Phase 3 trial is 5 to 20 years, compared with 5 to 15 years in the Phase 2 trial
- Both trials are US sites only, with most Phase 2 sites participating in Phase 3

NNZ-2591 FOR MULTIPLE NEURODEVELOPMENTAL DISORDERS

FIVE TIMES LARGER OPPORTUNITY FOR NNZ-2591

Disorder	Gene mutation	Published prevalence estimates	Potential patients		
			US ¹	Europe ¹	Asia ^{1, 2}
Phelan-McDermid	<i>SHANK3</i>	1/8,000 to 1/15,000 males and females	22,000	28,000	81,000
Angelman	<i>UBE3A</i>	1/12,000 to 1/24,000 males and females	14,000	18,000	52,000
Pitt Hopkins	<i>TCF4</i>	1/34,000 to 1/41,000 males and females	7,000	9,000	25,000
Prader-Willi	<i>15q11-q13</i>	1/10,000 to 1/30,000 males and females	13,000	16,000	47,000
			56,000	71,000	205,000

- ▣ **Current opportunity for NNZ-2591 is more than 5 times the Rett Syndrome opportunity³**
- ▣ **There are many other neurodevelopmental disorders potentially relevant for NNZ-2591 mechanism of action**

¹ Estimates derived by applying the mid-point of the prevalence estimate range to the populations under 60 years

² Asia comprises Japan, Korea, Taiwan, Israel and urban populations of China and Russia

³ Based on number of addressable patients globally

IDEAL ATTRIBUTES LEADING INTO PHASE 2

- ✓ Novel mechanism of action
- ✓ Clear and consistent efficacy in mouse models of each syndrome
- ✓ Biochemical effects in the brain and optimum dose confirmed
- ✓ Demonstrated high oral bioavailability and blood-brain barrier penetration
- ✓ IND-enabling program of non-clinical toxicology and CMC studies completed
- ✓ Proprietary drug substance manufacturing process with exceptional purity and high yield, administered as patient-friendly liquid dose
- ✓ Safe and well tolerated in Phase 1 trial
- ✓ Phase 2 plans confirmed at pre-IND meetings with FDA
- ✓ Orphan designations from FDA and EMA

KEY FEATURES OF FIRST PHASE 2 TRIALS

- ❑ Prioritising speed to data:
 - ❑ AS trial in Australia, PMS and PTHS trials in US
 - ❑ Up to 20 patients in each trial, all patients receive drug
- ❑ Maximising opportunity to demonstrate effects:
 - ❑ Pediatric patients
 - ❑ 13 weeks' treatment following well-characterised baseline period
- ❑ Confirm safety and PK in pediatric patients
- ❑ Assess treatment impact across multiple efficacy measures to select primary endpoint for registration trial
- ❑ Currently amending protocols to enhance safety monitoring following FDA review of IND applications

Overall aim – expedite data that enables subsequent trials to be designed as registration trials, commencing in 2023


STOCK INFORMATION (ASX: NEU)

Current risk-adjusted valuation per share (MST Access) - A\$3.93

52 week price range: A\$1.00 - A\$2.53


Current share register composition (126 million quoted shares – top 20 hold 50%)

NEU share price (A\$) 1 year



A\$35.0 million cash at 30 September 2021

THREE KEY DRIVERS TO TRANSFORM NEAR TERM VALUE



Realise Neuren's share of trofinetide value in the US through ACADIA's Phase 3 results and New Drug Application

Implement commercial strategy for trofinetide ex-North America, using US data for registration

Confirm efficacy of NNZ-2591 in Phase 2 trials for 4 valuable indications

CONTACT

Jon Pilcher, CEO

jpilcher@neurenpharma.com

+61 438 422 271